Suppr超能文献

肝细胞癌患者的第二原发性恶性肿瘤:一项基于人群的分析。

Second Primary Malignancies in Patients With Hepatocellular Carcinoma: A Population-Based Analysis.

作者信息

Kong Junjie, Yu Guangsheng, Si Wei, Li Guangbing, Chai Jiawei, Liu Yong, Liu Jun

机构信息

Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.

出版信息

Front Oncol. 2021 Aug 23;11:713637. doi: 10.3389/fonc.2021.713637. eCollection 2021.

Abstract

BACKGROUND

Second primary malignancy (SPM) is becoming a threat for the health of cancer survivors. However, data on the features and results of patients with hepatocellular carcinoma (HCC) with SPMs are scarce. This study aimed to explore the characteristics of HCC patients with SPMs and to screen HCC patients who are at a high risk of developing SPMs.

METHOD

HCC patients diagnosed between 2000 and 2014 in the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively analyzed. Eligible patients were divided into the only one primary malignancy and SPM groups. The Fine-Gray proportional subdistribution hazards model was used to explore the risk factors of developing SPMs, and a competing-risk model was established to predict the probability of developing SPMs for HCC patients after initial diagnosis. The calibration curves, concordance index (C-index), and decision curve analysis (DCA) were used to evaluate the performance of the nomogram.

RESULTS

A total of 40,314 HCC patients were identified, 1,593 (3.95%) of whom developed SPMs 2 months after the initial diagnosis with a maximum follow-up time of approximately 18 years. The 3-, 5-, and 10-year cumulative incidence of SPMs were 2.35%, 3.12%, and 4.51%, respectively. Age at initial diagnosis, extent of disease, tumor size, and treatment were identified as the independent risk factors of developing SPMs and integrated into the competing-risk nomogram. The C-index of the nomogram was 0.677 (95% confidence interval 0.676-0.678), and the calibration curves showed an excellent agreement between the nomogram prediction and the actual observations. Furthermore, DCA indicated that the nomogram had good net benefits in clinical scenarios.

CONCLUSIONS

HCC survivors remain at a high risk of developing SPMs. The development of SPMs was associated with the clinical features and treatment strategies. A competing-risk nomogram was constructed to help surgeons identify the patients who are at a high risk of developing SPMs and contribute to the further management of SPMs.

摘要

背景

第二原发性恶性肿瘤(SPM)正成为癌症幸存者健康的一大威胁。然而,关于肝细胞癌(HCC)合并SPM患者的特征和结果的数据却很匮乏。本研究旨在探讨HCC合并SPM患者的特征,并筛选出发生SPM风险较高的HCC患者。

方法

对监测、流行病学和最终结果(SEER)数据库中2000年至2014年诊断的HCC患者进行回顾性分析。符合条件的患者被分为仅有一个原发性恶性肿瘤组和SPM组。采用Fine-Gray比例分布风险模型探讨发生SPM的危险因素,并建立竞争风险模型以预测HCC患者初始诊断后发生SPM的概率。校准曲线、一致性指数(C指数)和决策曲线分析(DCA)用于评估列线图的性能。

结果

共纳入40314例HCC患者,其中1593例(3.95%)在初始诊断后2个月发生SPM,最长随访时间约18年。SPM的3年、5年和10年累积发病率分别为2.35%、3.12%和4.51%。初始诊断时的年龄、疾病范围、肿瘤大小和治疗被确定为发生SPM的独立危险因素,并纳入竞争风险列线图。列线图的C指数为0.677(95%置信区间0.676-0.678),校准曲线显示列线图预测与实际观察结果之间具有良好的一致性。此外,DCA表明列线图在临床场景中具有良好的净效益。

结论

HCC幸存者发生SPM的风险仍然很高。SPM的发生与临床特征和治疗策略有关。构建了竞争风险列线图,以帮助外科医生识别发生SPM风险较高的患者,并有助于SPM的进一步管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ab/8420091/1af42f005f65/fonc-11-713637-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验